Colorectal Cancer Branch, Division of Translational and Clinical Research I, Research Institute, National Cancer Center, Goyang-si, Republic of Korea.
BMC Cancer. 2010 Feb 23;10:55. doi: 10.1186/1471-2407-10-55.
Non-Hodgkin lymphoma (NHL) is a hematologic malignancy for which good diagnostic markers are lacking. Despite continued improvement in our understanding of NHL, efforts to identify diagnostic markers have yielded dismal results. Here, we translated low-mass-ion information in urine samples from patients with NHL into a diagnostic marker.
To minimize experimental error, we tested variable parameters before MALDI-TOF analysis of low-mass ions in urine. Urine from 30 controls and 30 NHL patients was analyzed as a training set for NHL prediction. All individual peak areas were normalized to total area up to 1000 m/z. The training set analysis was repeated four times. Low-mass peaks that were not affected by changes in experimental conditions were collected using MarkerView software. Human Metabolome Database (HMDB) searches and ESI LC-MS/MS analyses were used to identify low-mass ions that exhibited differential patterns in control and NHL urines. Identified low-mass ions were validated in a blinded fashion in 95 controls and 66 NHL urines to determine their ability to discriminate NHL patients from controls.
The 30 highest-ranking low-mass-ion peaks were selected from the 60-urine training set, and three low-mass-ion peaks with high intensity were selected for identification. Of these, a 137.08-m/z ion showed lower mass-peak intensity in urines of NHL patients, a result that was validated in a 161-urine blind validation set (95 controls and 66 NHL urines). The 130.08-m/z ion was identified from HMDB searches and ESI LC-MS/MS analyses as hypoxanthine (HX). The HX concentration in urines of NHL patients was significantly decreased (P < 0.001) and was correlated with the mass-peak area of the 137.08-m/z ion. At an HX concentration cutoff of 17.4 microM, sensitivity and specificity were 79.2% and 78.4%, respectively.
The present study represents a good example of low-mass-ion profiling in the setting of disease screening using urine. This technique can be a powerful non-invasive diagnostic tool with high sensitivity and specificity for NHL screening. Furthermore, HX identified in the study may be a useful single urine marker for NHL screening.
非霍奇金淋巴瘤(NHL)是一种血液恶性肿瘤,缺乏良好的诊断标志物。尽管我们对 NHL 的理解不断提高,但寻找诊断标志物的努力却收效甚微。在这里,我们将 NHL 患者尿液中的低质量离子信息转化为诊断标志物。
为了最大限度地减少实验误差,我们在 MALDI-TOF 分析尿液中的低质量离子之前测试了变量参数。将 30 名对照者和 30 名 NHL 患者的尿液作为 NHL 预测的训练集进行分析。将所有个体峰面积归一化为高达 1000 m/z 的总面积。重复四次进行训练集分析。使用 MarkerView 软件收集不受实验条件变化影响的低质量峰。使用人代谢组数据库(HMDB)搜索和 ESI LC-MS/MS 分析来鉴定在对照者和 NHL 尿液中表现出差异模式的低质量离子。在 95 名对照者和 66 名 NHL 尿液中以盲法验证鉴定的低质量离子,以确定它们区分 NHL 患者与对照者的能力。
从 60 例尿液训练集中选择了 30 个排名最高的低质量离子峰,选择了 3 个高强度的低质量离子峰进行鉴定。其中,137.08 m/z 离子在 NHL 患者尿液中的质量峰强度较低,这一结果在 161 例盲法验证集中得到验证(95 名对照者和 66 名 NHL 尿液)。通过 HMDB 搜索和 ESI LC-MS/MS 分析,130.08 m/z 离子被鉴定为次黄嘌呤(HX)。NHL 患者尿液中的 HX 浓度显著降低(P < 0.001),与 137.08 m/z 离子的质量峰面积相关。在 HX 浓度截止值为 17.4 microM 时,灵敏度和特异性分别为 79.2%和 78.4%。
本研究代表了使用尿液进行疾病筛查的低质量离子分析的一个很好的例子。该技术可以成为一种强大的非侵入性诊断工具,具有 NHL 筛查的高灵敏度和特异性。此外,本研究中鉴定的 HX 可能是 NHL 筛查的有用单一尿液标志物。